Help
Posted Thu, Feb, 07,2013
Published today in Magnetic Resonance Insights is a new original research article by Ravi Bhargava and Michelle Noga. Read more about this paper below:
Title
Safety and Efficacy of Gadobutrol-Enhanced MRI in Patients Aged Under 2 Years—A Single-Center, Observational Study
Abstract
Gadobutrol is a 1-molar gadolinium-based contrast agent with well-characterized safety and efficacy for magnetic resonance imaging (MRI) in adults and children ≥ 2 years old. This observational study assessed gadobutrol-enhanced MRI in children < 2 years of age. Sixty infants (mean age 11.1 months) underwent MRI using gadobutrol at standard dose of 0.1 mL/kg (0.1 mmol/kg) body weight. MRI examinations included brain, spine, and neck (n = 24), subcutaneous soft tissues (n = 14), chest, abdomen, and pelvis (n = 12), musculoskeletal system (n = 7) and vascular system (n = 3). No patients experienced adverse events related to gadobutrol injection. In 57 patients with confirmed diagnoses, gadobutrol-enhanced MRI provided findings consistent with confirmed pathologies. This study indicates that gadobutrol at a standard dose for MRI is safe in patients aged < 2 years and provides diagnostic information for multiple pathologies.
Click here to learn more about the article, download it and comment
Posted in: Articles Published
News Categories
Thu 08 Oct, 2015
Published This Week (5th - 9th October)Thu 08 Oct, 2015
Biomarker Insights Paper Endorsed by Editor in ChiefWed 07 Oct, 2015
Interview with Professor Jamie DaviesWe found Bioinformatics and Biology insights very supportive and quick in guiding us in submitting our manuscript. The review of the manuscript was also very prompt. We also found that the review was fair and prompt and that was the most important thing for us. It was a very interesting experience for us. We also liked the video abstract service, which is very novel and encouraging for authors.
Facebook Google+ Twitter
Pinterest Tumblr YouTube